Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective
Gliomas are the most common primary brain tumors. Among them, glioblastoma (GBM) possesses the most malignant phenotype. Despite the current standard therapy using an alkylating anticancer agent, temozolomide, most patients with GBM die within 2 years. Novel chemotherapeutic agents are urgently need...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/72600 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Drug Repositioning for the Treatment of Glioma: Current State and Future Perspective
- Current Applications of 5-ALA in Glioma Diagnostics and Therapy
- Smart Drug-Delivery Systems in the Treatment of Rheumatoid Arthritis: Current, Future Perspectives
- Drug repositioning : bringing new life to shelved assets and existing drugs /
- Glioma Proteomics: Methods and Current Perspective
- Introductory Chapter: Repurposed Drugs – Current State and Future Perspectives
- Current Mesothelioma Treatment and Future Perspectives